Introduction to the CANWARD Study (2007-2009).

[1]  J. Karlowsky,et al.  Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[2]  M. Mulvey,et al.  Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[3]  J. Karlowsky,et al.  In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[4]  J. Blondeau,et al.  Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[5]  S. Poutanen,et al.  In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[6]  M. Mulvey,et al.  Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[7]  R. Rennie,et al.  Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[8]  M. Mulvey,et al.  Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.

[9]  F. Martínez Sagasti,et al.  Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. , 2010, JAMA.

[10]  K. Reed,et al.  Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008. , 2010, Diagnostic microbiology and infectious disease.

[11]  B. Murray,et al.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.

[12]  A. Kennedy,et al.  Epidemiology and Virulence of Community-Associated MRSA , 2009 .

[13]  Qiwen Yang,et al.  Phenotypic and Genotypic Characterization of Enterobacteriaceae with Decreased Susceptibility to Carbapenems: Results from Large Hospital-Based Surveillance Studies in China , 2009, Antimicrobial Agents and Chemotherapy.

[14]  M. Mulvey,et al.  Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results from CANWARD 2007. , 2009 .

[15]  R. Bonomo,et al.  The continuing challenge of ESBLs. , 2007, Current opinion in pharmacology.

[16]  B. Wickes,et al.  First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System , 2007, Antimicrobial Agents and Chemotherapy.

[17]  K. Bush,et al.  Carbapenemases: the Versatile β-Lactamases , 2007, Clinical Microbiology Reviews.